Ameritas Investment Partners
RLMD icon

Ameritas Investment Partners’s Relmada Therapeutics RLMD Stock Holding History

Ameritas Investment Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.4K Buy
+8,582
New +$60K ﹤0.01% 2160
2023
Q2 		– Sell
-1,926
Closed -$4.35K – 3195
2023
Q1 		$4.35K Hold
1,926
– – ﹤0.01% 2885
2022
Q4 		$8.51K Hold
1,926
– – ﹤0.01% 2846
2022
Q3 		$71K Hold
1,926
– – ﹤0.01% 1732
2022
Q2 		$36K Hold
1,926
– – ﹤0.01% 2209
2022
Q1 		$52K Buy
1,926
+684
+55% +$14.1K ﹤0.01% 2048
2021
Q4 		$28K Hold
1,242
– – ﹤0.01% 2482
2021
Q3 		$33K Hold
1,242
– – ﹤0.01% 2419
2021
Q2 		$40K Hold
1,242
– – ﹤0.01% 2336
2021
Q1 		$44K Hold
1,242
– – ﹤0.01% 2164
2020
Q4 		$40K Hold
1,242
– – ﹤0.01% 2112
2020
Q3 		$47K Hold
1,242
– – ﹤0.01% 1880
2020
Q2 		$56K Buy
+1,242
New +$52.5K ﹤0.01% 1761

Other funds holding RLMD

Jupiter Topco
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ameritas Investment Partners's RLMD Position: Q2 2026 in Review

Ameritas Investment Partners opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 8,582 shares worth $59.4K. The stake represents ﹤0.01% of the portfolio and ranks #2160 among its holdings. This is a return to the name: Ameritas Investment Partners previously reported a position in RLMD as recently as Q1 2023.

Ameritas Investment Partners first reported a position in RLMD in Q2 2020 and has held it in 13 quarters since. The position peaked at $71K in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Ameritas Investment Partners held 8,582 shares of Relmada Therapeutics worth $59.4K as of Q2 2026.
  • Relmada Therapeutics was a new Ameritas Investment Partners position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2160 holding.
  • Ameritas Investment Partners first reported a position in Relmada Therapeutics in Q2 2020 and has held it in 13 quarters since.
  • Ameritas Investment Partners's Relmada Therapeutics position peaked at $71K in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.